BIND Therapeutics Appoints Gregory I. Berk, M.D. as Chief Medical Officer

  BIND Therapeutics Appoints Gregory I. Berk, M.D. as Chief Medical Officer

Business Wire

CAMBRIDGE, Mass. -- April 02, 2013

BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new
class of highly selective targeted and programmable therapeutics called
Accurins^TM, today announced the appointment of Gregory I. Berk, M.D. as Chief
Medical Officer, effective immediately. Dr. Berk will be responsible for
leading the Company's global clinical development strategy and clinical
operations.

“As an oncologist with more than 20 years of global industry and academic
experience, Greg’s expertise is proving invaluable as we aggressively move
forward with our targeted and programmable therapeutic pipeline, including
BIND-014, our lead Accurin for the treatment of solid tumors which is poised
to enter Phase 2 clinical trials in the coming months,” said Scott Minick,
President and Chief Executive Officer of BIND Therapeutics. “Greg’s clinical
vision and proven leadership, as well as his extensive medical and research
experience, will strengthen our clinical development efforts and support the
future progress of our product pipeline.”

“BIND’s targeted and programmable nanoparticle technology is a paradigm shift
in oncology therapeutics and has the potential to significantly improve
patient outcomes,” commented Dr. Berk. “I am excited to be joining BIND,
particularly at this stage, as we prepare to advance a pipeline of novel
Accurins, including BIND-014 for cancer, which has demonstrated very strong
early clinical results to date that show how BIND’s technology can create
therapies with new levels of selectivity and targeting.”

Dr. Berk is an oncology veteran with more than 20 years of industry and
academic experience. Prior to joining BIND, Dr. Berk served as Chief Medical
Officer of Intellikine, a clinical stage company developing small molecule
drugs targeting signal transduction networks, which was acquired by Takeda
Pharmaceutical Company Limited. Dr. Berk was previously Senior Vice President
of Global Clinical Development at Abraxis BioScience, where he was responsible
for the company’s overall clinical strategy, including efforts to expand the
indications for their lead clinical program (Abraxane®), as well as oversee
the clinical development of their entire pipeline. Dr. Berk also served on the
integration leadership team during the Celgene acquisition of Abraxis in 2010.
Dr. Berk obtained his medical degree from Case Western Reserve University, and
completed his internship, residency, and fellowship in internal medicine,
hematology, and medical oncology, at the Weill Medical College of Cornell
University and New York Presbyterian Hospital, where he also served as a
faculty member from 1989-2004. During this time Dr. Berk served as an
investigator on several industry-sponsored and cooperative group clinical
trials, including the pivotal trials for Gleevec® and Avastin®.

About BIND Therapeutics

BIND Therapeutics is a clinical-stage biopharmaceutical company developing a
new class of highly selective targeted and programmable therapeutics called
Accurins^TM. BIND’s Medicinal Nanoengineering^TM platform enables the design,
engineering and manufacturing of Accurins with unprecedented control over drug
properties to maximize trafficking to disease sites, dramatically enhancing
efficacy while minimizing toxicities.

BIND is developing a pipeline of novel Accurins that hold extraordinary
potential to become best-in-class drugs and improve patient outcomes in the
areas of oncology, inflammatory diseases and cardiovascular disorders. BIND's
lead product candidate, BIND-014, is currently in Phase 1 clinical testing in
cancer patients and is designed to selectively target a surface protein
upregulated in a broad range of solid tumors. BIND also develops Accurins in
collaboration with pharmaceutical and biotechnology partners to enable
promising pipeline candidates to achieve their full potential and to utilize
selective targeting to transform the performance of important existing drug
products.

BIND is backed by leading investors, Polaris Partners, Flagship Ventures, ARCH
Venture Partners, NanoDimension, DHK Investments, EndeavourVision and Rusnano.
BIND was founded on proprietary technology from the laboratories of two
leaders in the field of nanomedicine, Professors Robert Langer, David H. Koch
Institute Professor of the Massachusetts Institute of Technology (MIT) and
Omid Farokhzad, Associate Professor of Harvard Medical School. For more
information, please visit the company's web site at www.bindbio.com.

Contact:

The Yates Network
Gina Nugent, 617-460-3579